CEA for CIFF AcceleraTE Trachoma Elimination 

The Project

The AcceleraTE Trachoma Elimination investment aimed to accelerate the elimination of trachoma in Africa, encourage integration across the Preventive Chemotherapy (PC) of Neglected Tropical Diseases (NTDs) and provide evidence of a mechanism to reduce mortality in children under five years of age. The Children’s Investment Fund Foundation (CIFF) and its partners Bill and Melinda Gates Foundation (BMGF), ELMA Philanthropies, and Virgin Unite funded this five-year investment across 11 African countries: Benin, Burkina Faso, Cameroon, Cote d’Ivoire, Ethiopia, Guinea-Bissau, Kenya, Nigeria, Senegal and Zimbabwe. 

Sightsavers works with partners in developing countries to treat and prevent avoidable blindness in the world’s poorest countries and through the AcceleraTE investment, Sightsavers implemented the World Health Organization (WHO) endorsed SAFE (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) strategy in the 11 African countries. 

CIFF commissioned Verian Global (previously Kantar) to assess the implementation of all Sightsavers-led activities across four countries. The process evaluation and cost-effectiveness analysis focused on Nigeria, Senegal, Zimbabwe and Ethiopia. 

LAMP conducted the cost-effectiveness analysis component, comparing the programme’s costs in each of the four countries and any positive impacts identified through the impact evaluation. The analysis examined the question: what is the cost-effectiveness of the AcceleraTE (ATE) investment?